Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Xi'an Jiaotong UniversityNo recent work listed

Jianjun Lei

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8258-705X; OpenAlex author ID A5100374943. Sources: OpenAlex.

Their work

Papers
31 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
49
Papers, trials and grants by year

2012: 3 papers · 2013: 1 paper · 2014: 5 papers · 2015: 6 papers · 2016: 6 papers · 2017: 2 papers · 2018: 2 papers · 2019: 2 papers · 2020: 3 papers · 2021: 1 paper

Papers 31

  1. The EGFR-HSF1 axis accelerates the tumorigenesis of pancreatic cancer. Co-author DOI 10.1186/s13046-020-01823-4↗
  2. Cav-1 Ablation in Pancreatic Stellate Cells Promotes Pancreatic Cancer Growth through Nrf2-Induced shh Signaling. Last author DOI 10.1155/2020/1868764↗
  3. Resveratrol Ameliorates the Malignant Progression of Pancreatic Cancer by Inhibiting Hypoxia-induced Pancreatic Stellate Cell Activation. Co-author DOI 10.1177/0963689720929987↗
  4. Curcumin inhibits pancreatic cancer cell invasion and EMT by interfering with tumor‑stromal crosstalk under hypoxic conditions via the IL‑6/ERK/NF‑κB axis. Co-author DOI 10.3892/or.2020.7600↗
  5. Hypoxia-driven paracrine osteopontin/integrin αvβ3 signaling promotes pancreatic cancer cell epithelial-mesenchymal transition and cancer stem cell-like proper… Co-author DOI 10.1002/1878-0261.12399↗
  6. Hypoxia-inducible Factor-1α Mediates Hyperglycemia-induced Pancreatic Cancer Glycolysis. Last author DOI 10.2174/1871520619666190626120359↗
  7. Paracrine HGF/c-MET enhances the stem cell-like potential and glycolysis of pancreatic cancer cells via activation of YAP/HIF-1α. Last author DOI 10.1016/j.yexcr.2018.07.041↗
  8. Inhibiting YAP expression suppresses pancreatic cancer progression by disrupting tumor-stromal interactions. Co-author DOI 10.1186/s13046-018-0740-4↗
  9. Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2016.10.019↗
  10. Lipoxin A4 reverses mesenchymal phenotypes to attenuate invasion and metastasis via the inhibition of autocrine TGF-β1 signaling in pancreatic cancer. Co-author DOI 10.1186/s13046-017-0655-5↗
  11. The Relevance of Nrf2 Pathway and Autophagy in Pancreatic Cancer Cells upon Stimulation of Reactive Oxygen Species. Co-author DOI 10.1155/2016/3897250↗
  12. Lipoxin A4 Attenuates Cell Invasion by Inhibiting ROS/ERK/MMP Pathway in Pancreatic Cancer. Co-author DOI 10.1155/2016/6815727↗
  13. β2-adrenogenic signaling regulates NNK-induced pancreatic cancer progression via upregulation of HIF-1α. First author DOI 10.18632/oncotarget.5677↗
  14. Pancreatic stellate cells contribute pancreatic cancer pain via activation of sHH signaling pathway. Co-author DOI 10.18632/oncotarget.7776↗
  15. Resveratrol inhibits hypoxia-driven ROS-induced invasive and migratory ability of pancreatic cancer cells via suppression of the Hedgehog signaling pathway. Co-author DOI 10.3892/or.2015.4504↗
  16. Curcumin inhibits hypoxia-induced epithelial‑mesenchymal transition in pancreatic cancer cells via suppression of the hedgehog signaling pathway. Co-author DOI 10.3892/or.2016.4709↗
  17. Hyperglycemic tumor microenvironment induces perineural invasion in pancreatic cancer. Co-author DOI 10.1080/15384047.2015.1040952↗
  18. Resveratrol in the treatment of pancreatic cancer. Co-author DOI 10.1111/nyas.12837↗
  19. Overexpression of Nodal induces a metastatic phenotype in pancreatic cancer cells via the Smad2/3 pathway. Co-author DOI 10.18632/oncotarget.2686↗
  20. Stromal-derived factor-1α/CXCL12-CXCR4 chemotactic pathway promotes perineural invasion in pancreatic cancer. Co-author DOI 10.18632/oncotarget.3069↗
  21. Ginkgolic acid suppresses the development of pancreatic cancer by inhibiting pathways driving lipogenesis. Co-author DOI 10.18632/oncotarget.3663↗
  22. miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases. Co-author DOI 10.18632/oncotarget.3686↗
  23. α-Mangostin inhibits hypoxia-driven ROS-induced PSC activation and pancreatic cancer cell invasion. Co-author DOI 10.1016/j.canlet.2014.02.003↗
  24. Upregulated miR-106a plays an oncogenic role in pancreatic cancer. Co-author DOI 10.1016/j.febslet.2014.01.007↗
  25. α-Mangostin suppresses the viability and epithelial-mesenchymal transition of pancreatic cancer cells by downregulating the PI3K/Akt pathway. Co-author DOI 10.1155/2014/546353↗
  26. Sonic hedgehog paracrine signaling activates stromal cells to promote perineural invasion in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-13-3426↗
  27. The Activation of β1-integrin by Type I Collagen Coupling with the Hedgehog Pathway Promotes the Epithelial-Mesenchymal Transition in Pancreatic Cancer. Co-author DOI 10.2174/1568009614666140402105101↗
  28. Hedgehog signaling regulates hypoxia induced epithelial to mesenchymal transition and invasion in pancreatic cancer cells via a ligand-independent manner. Co-author DOI 10.1186/1476-4598-12-66↗
  29. SDF-1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelial-mesenchymal transition in vitro through non-canonical activation of Hedgehog pathw… Co-author DOI 10.1016/j.canlet.2012.02.035↗
  30. Therapeutic potential of perineural invasion, hypoxia and desmoplasia in pancreatic cancer. Co-author DOI 10.2174/13816128112092395↗
  31. Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment. Co-author DOI 10.2174/13816128112092404↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qingyong Ma · 30 shared papers, 2012–2021 · strength 1.76
  2. Wanxing Duan · 26 shared papers, 2012–2021 · strength 1.38
  3. Qinhong Xu · 25 shared papers, 2012–2020 · strength 1.23
  4. Xuqi Li · 24 shared papers, 2012–2020 · strength 1.21
  5. Zheng Wang · 17 shared papers, 2012–2021 · strength 1.08
  6. Jiguang Ma · 19 shared papers, 2013–2021 · strength 1.06
  7. Zheng Wu · 12 shared papers, 2013–2021 · strength 0.74
  8. Erxi Wu · 16 shared papers, 2012–2020 · strength 0.71
  9. Zhengdong Jiang · 10 shared papers, 2015–2018 · strength 0.52
  10. Liankang Sun · 6 shared papers, 2017–2020 · strength 0.51
  11. Weikun Qian · 5 shared papers, 2018–2021 · strength 0.47
  12. Liang Han · 7 shared papers, 2014–2021 · strength 0.41
  13. Ke Chen · 5 shared papers, 2016–2021 · strength 0.39
  14. Liang Han · 7 shared papers, 2014–2020 · strength 0.38
  15. Jie Li · 4 shared papers, 2018–2021 · strength 0.37
  16. Wěi Li · 4 shared papers, 2016–2020 · strength 0.37
  17. Liang Zong · 7 shared papers, 2015–2018 · strength 0.35
  18. Wei Li · 6 shared papers, 2014–2020 · strength 0.32
  19. Cancan Zhou · 4 shared papers, 2017–2021 · strength 0.31
  20. Ying Xiao · 3 shared papers, 2019–2021 · strength 0.30
  21. Tao Qin · 3 shared papers, 2019–2021 · strength 0.30
  22. Lun Zhang · 5 shared papers, 2015–2016 · strength 0.23
  23. Liang Cheng · 3 shared papers, 2018–2019 · strength 0.23
  24. Zhenhua Ma · 5 shared papers, 2014–2017 · strength 0.22
  25. Xin Chen · 4 shared papers, 2015–2018 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.